{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:12:31Z","timestamp":1789499551007,"version":"build-2803163510"},"reference-count":198,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802542"],"award-info":[{"award-number":["81802542"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In recent years, systematic treatment has made great progress in genitourinary tumors. However, some patients develop resistance to the treatments, resulting in an increase in mortality. Circular RNAs (circRNAs) form a class of non-coding RNAs with high stability and significant clinical relevance. Accumulating evidence indicates that circRNAs play a vital role in cancer development and tumor chemotherapy resistance. This review summarizes the molecular and cellular mechanisms of drug resistance mediated by circRNAs to common drugs used in the treatment of genitourinary tumors. Several circRNAs were identified to regulate the responsiveness to systemic treatments in genitourinary tumors, including chemotherapies such as cisplatin and targeted therapies such as enzalutamide. Canonically, cicrRNAs participate in the competing endogenous RNA (ceRNA) network, or in some cases directly interact with proteins, regulate downstream pathways, and even some circRNAs have the potential to produce proteins or polypeptides. Several cellular mechanisms were involved in circRNA-dependent drug resistance, including autophagy, cancer stem cells, epithelial-mesenchymal transition, and exosomes. The potential clinical prospect of circRNAs in regulating tumor drug resistance was also discussed.<\/jats:p>","DOI":"10.3390\/cancers14040866","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T21:19:06Z","timestamp":1644441546000},"page":"866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-2306","authenticated-orcid":false,"given":"Gongwei","family":"Long","sequence":"first","affiliation":[{"name":"Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siquan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runlin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-6257","authenticated-orcid":false,"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Hubei Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.21601","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u20142019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2017.08.010","article-title":"Systemic treatment of renal cell cancer: A comprehensive review","volume":"60","author":"Kempf","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of Advanced Prostate Cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/15476286.2015.1020271","article-title":"Regulation of circRNA biogenesis","volume":"12","author":"Chen","year":"2015","journal-title":"RNA Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00018-019-03345-5","article-title":"CircRNA: A rising star in gastric cancer","volume":"77","author":"Li","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.celrep.2014.12.019","article-title":"Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals","volume":"10","author":"Ivanov","year":"2015","journal-title":"Cell Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molcel.2014.08.019","article-title":"circRNA biogenesis competes with pre-mRNA splicing","volume":"56","author":"Meyer","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2016.03.020","article-title":"Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations","volume":"165","author":"Guarnerio","year":"2016","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E5207","DOI":"10.1073\/pnas.1617467114","article-title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing","volume":"114","author":"Fei","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"D925","DOI":"10.1093\/nar\/gkx863","article-title":"CSCD: A database for cancer-specific circular RNAs","volume":"46","author":"Xia","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/bib\/bby006","article-title":"Microarray is an efficient tool for circRNA profiling","volume":"20","author":"Li","year":"2019","journal-title":"Brief. Bioinform."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2775","DOI":"10.21769\/BioProtoc.2775","article-title":"Detection and Analysis of Circular RNAs by RT-PCR","volume":"8","author":"Panda","year":"2018","journal-title":"Bio Protoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt.2890","article-title":"Detecting and characterizing circular RNAs","volume":"32","author":"Jeck","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nsmb.2959","article-title":"Exon-intron circular RNAs regulate transcription in the nucleus","volume":"22","author":"Li","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.cell.2015.02.014","article-title":"The RNA binding protein quaking regulates formation of circRNAs","volume":"160","author":"Conn","year":"2015","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molcel.2017.02.017","article-title":"Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis","volume":"66","author":"Legnini","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/eurheartj\/ehv713","article-title":"A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223","volume":"37","author":"Wang","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmet.2018.01.010","article-title":"Circular RNAs as novel regulators of \u03b2-cell functions in normal and disease conditions","volume":"9","author":"Stoll","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101058","DOI":"10.1016\/j.arr.2020.101058","article-title":"Functional roles of circular RNAs in Alzheimer\u2019s disease","volume":"60","author":"Huang","year":"2020","journal-title":"Ageing Res. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-020-01300-8","article-title":"Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer","volume":"20","author":"Yang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105968","DOI":"10.1016\/j.biocel.2021.105968","article-title":"Roles of circRNAs in prostate cancer: Expression, mechanism, application and potential","volume":"134","author":"Zhang","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-020-01266-7","article-title":"Circular RNAs in renal cell carcinoma: Implications for tumorigenesis, diagnosis, and therapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition\u2014Novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., and Belaud-Rotureau, M.A. (2020). Immunotherapy in Renal Cell Carcinoma: The Future Is Now. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072532"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pereira, M., and Vale, N. (2022). Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine. Molecules, 27.","DOI":"10.3390\/molecules27010291"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrclinonc.2016.188","article-title":"Systemic, perioperative management of muscle-invasive bladder cancer and future horizons","volume":"14","author":"Funt","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fmed.2017.00013","article-title":"Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib","volume":"4","author":"Corrales","year":"2017","journal-title":"Front. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_42","first-page":"195","article-title":"Gemcitabine in pre-treated advanced renal carcinoma: A feasibility study","volume":"20","author":"Casali","year":"2001","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1002\/cncr.29503","article-title":"Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma","volume":"121","author":"Michaelson","year":"2015","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","article-title":"Gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"23","author":"Binenbaum","year":"2015","journal-title":"Drug Resist. Updat"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.stemcr.2017.07.009","article-title":"Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells","volume":"9","author":"Hu","year":"2017","journal-title":"Stem. Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbrc.2019.08.093","article-title":"Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation","volume":"519","author":"Yan","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","unstructured":"Cai, F., Li, J., Zhang, J., and Huang, S. (Cancer Biother Radiopharm., 2020). Knockdown of Circ_CCNB2 Sensitizes Prostate Cancer to Radiation Through Repressing Autophagy by the miR-30b-5p\/KIF18A Axis, Cancer Biother Radiopharm., Ahead of Print."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"B\u00e6k M\u00f8ller, N., Budolfsen, C., Grimm, D., Kr\u00fcger, M., Infanger, M., Wehland, M., and Magnusson, N.E. (2019). Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194712"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2012.59","article-title":"Treatment selection in metastatic renal cell carcinoma: Expert consensus","volume":"9","author":"Escudier","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14737140.2017.1272415","article-title":"Sunitinib in kidney cancer: 10 years of experience and development","volume":"17","author":"Nassif","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.003","article-title":"Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184\/GPCPD1\/lysophosphatidic acid axis","volume":"523","author":"Huang","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/epi-2020-0385","article-title":"CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma","volume":"13","author":"Zeng","year":"2021","journal-title":"Epigenomics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_54","first-page":"507","article-title":"Bladder Cancer: Diagnosis and Treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00345-018-2591-1","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: How, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.2147\/CMAR.S263083","article-title":"Circular RNA circRNA_103809 Accelerates Bladder Cancer Progression and Enhances Chemo-Resistance by Activation of miR-516a-5p\/FBXL18 Axis","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_59","first-page":"6064","article-title":"Circular RNA hsa_circ_103809 promotes cell migration and invasion of gastric cancer cells by binding to microRNA-101-3p","volume":"24","author":"Huang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_60","first-page":"3725","article-title":"circ_103809 promotes breast cancer progression by regulating the PI3K\/AKT signaling pathway","volume":"19","author":"Qiu","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_61","first-page":"555","article-title":"Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620","volume":"23","author":"Li","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bbrc.2018.09.073","article-title":"Hsa_circRNA_103809 regulated the cell proliferation and migration in colorectal cancer via miR-532-3p \/ FOXO4 axis","volume":"505","author":"Bian","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.7150\/jca.39722","article-title":"Circular RNA CircHIPK3 Promotes Gemcitabine Sensitivity in Bladder Cancer","volume":"11","author":"Xie","year":"2020","journal-title":"J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/CMAR.S239326","article-title":"CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.2147\/CMAR.S307595","article-title":"Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286","volume":"13","author":"Ni","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_66","first-page":"537","article-title":"Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421\/ZIC5 Axis in Glioma","volume":"36","author":"Han","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ebiom.2019.09.051","article-title":"circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637","volume":"48","author":"Zhang","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1515\/med-2021-0299","article-title":"Circular RNA VANGL1 knockdown suppressed viability, promoted apoptosis, and increased doxorubicin sensitivity through targeting miR-145-5p to regulate SOX4 in bladder cancer cells","volume":"16","author":"Zhu","year":"2021","journal-title":"Open Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/jcp.27162","article-title":"Circular RNA circ-VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR-605-3p\/VANGL1 pathway","volume":"234","author":"Zeng","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_70","first-page":"949","article-title":"Circ-VANGL1 promotes the progression of osteoporosis by absorbing miRNA-217 to regulate RUNX2 expression","volume":"23","author":"Yang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2021.10.017","article-title":"Cisplatin, Neoadjuvant Chemotherapy and Bladder Cancer","volume":"159","author":"Herr","year":"2022","journal-title":"Urology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Iacovino, M.L., Miceli, C.C., De Felice, M., Barone, B., Pompella, L., Chiancone, F., Di Zazzo, E., Tirino, G., Della Corte, C.M., and Imbimbo, C. (2022). Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031133"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: A 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.048","article-title":"652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG\/AFU VESPER V05 phase III trial","volume":"32","author":"Pfister","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-21-1518","article-title":"Circ0008399 interaction with WTAP promotes assembly and activity of the m6A methyltransferase complex and promotes cisplatin resistance in bladder cancer","volume":"81","author":"Wei","year":"2021","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41419-019-1937-y","article-title":"A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms","volume":"10","author":"Priem","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7150\/ijbs.26826","article-title":"Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance","volume":"15","author":"Su","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"110059","DOI":"10.1016\/j.biopha.2020.110059","article-title":"A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer","volume":"126","author":"Gong","year":"2020","journal-title":"Biomed. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e48467","DOI":"10.15252\/embr.201948467","article-title":"Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion","volume":"21","author":"Chen","year":"2020","journal-title":"EMBO Rep."},{"key":"ref_81","first-page":"1017","article-title":"circ-FNTA accelerates proliferation and invasion of bladder cancer","volume":"19","author":"Tian","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-021-01360-4","article-title":"CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutS\u03b1\/ATM-p73 axis in bladder cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11011-021-00853-x","article-title":"Circular RNA circLIFR regulates the proliferation, migration, invasion and apoptosis of human vascular smooth muscle cells via the miR-1299\/KDR axis","volume":"37","author":"Zhang","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"590478","DOI":"10.3389\/fcell.2020.590478","article-title":"The Emerging Picture of the Roles of CircRNA-CDR1as in Cancer","volume":"8","author":"Jiang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/1878-0261.12523","article-title":"Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition","volume":"13","author":"Yuan","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1159\/000489208","article-title":"CircRNA-Cdr1as Exerts Anti-Oncogenic Functions in Bladder Cancer by Sponging MicroRNA-135a","volume":"46","author":"Li","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12935-020-01390-w","article-title":"CircRNA CDR1as\/miR-641\/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)","volume":"20","author":"Zhao","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtn.2019.07.012","article-title":"Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression","volume":"18","author":"Zhao","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"109771","DOI":"10.1016\/j.biopha.2019.109771","article-title":"Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR\/PI3K signaling pathway in lung adenocarcinoma","volume":"123","author":"Mao","year":"2020","journal-title":"Biomed. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1111\/jcmm.14171","article-title":"Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7","volume":"23","author":"Yang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4149\/neo_2018_180318N185","article-title":"Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance","volume":"66","author":"Chi","year":"2019","journal-title":"Neoplasma"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ctrv.2018.08.005","article-title":"De novo metastatic castration sensitive prostate cancer: State of art and future perspectives","volume":"70","author":"Mosillo","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/aja.2008.21","article-title":"Diagnostic strategies and the incidence of prostate cancer: Reasons for the low reported incidence of prostate cancer in China","volume":"11","author":"Zhang","year":"2009","journal-title":"Asian J. Androl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrd.2016.120","article-title":"Drug discovery in advanced prostate cancer: Translating biology into therapy","volume":"15","author":"Yap","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low\u2014And high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"605686","DOI":"10.3389\/fcell.2021.605686","article-title":"Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer","volume":"9","author":"Greene","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.omtn.2019.10.015","article-title":"Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene","volume":"18","author":"Luo","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1038\/s41388-019-0947-7","article-title":"Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer","volume":"38","author":"Cao","year":"2019","journal-title":"Oncogene"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12935-020-01421-6","article-title":"Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7","volume":"20","author":"Gao","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10528-021-10080-9","article-title":"Hsa_circ_0006404 and hsa_circ_0000735 Regulated Ovarian Cancer Response to Docetaxel Treatment via Regulating p-GP Expression","volume":"60","author":"Chen","year":"2021","journal-title":"Biochem Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.2147\/OTT.S253474","article-title":"Downregulation of Hsa_circ_0000735 Inhibits the Proliferation, Migration, Invasion, and Glycolysis in Non-small-cell Lung Cancer by Targeting miR-940\/BMPER Axis","volume":"13","author":"Huang","year":"2020","journal-title":"Oncol. Targets Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"644397","DOI":"10.3389\/fcell.2021.644397","article-title":"Circular RNA circ_0057558 Controls Prostate Cancer Cell Proliferation Through Regulating miR-206\/USP33\/c-Myc Axis","volume":"9","author":"Ding","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41419-021-04090-z","article-title":"Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1\/AMPK signaling through targeting miR-206","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2147\/DDDT.S300376","article-title":"Exosomal Circ-XIAP Promotes Docetaxel Resistance in Prostate Cancer by Regulating miR-1182\/TPD52 Axis","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41419-019-2028-9","article-title":"Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAP","volume":"10","author":"Feng","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","article-title":"Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel","volume":"468","author":"Shen","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"166045","DOI":"10.1016\/j.bbadis.2020.166045","article-title":"circFOXO3: Going around the mechanistic networks in cancer by interfering with miRNAs regulatory networks","volume":"1867","author":"Drula","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/neuonc\/noz128","article-title":"CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5","volume":"21","author":"Zhang","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"144798","DOI":"10.1016\/j.gene.2020.144798","article-title":"CircFOXO3 functions as a molecular sponge for miR-143-3p to promote the progression of gastric carcinoma via upregulating USP44","volume":"753","author":"Xiang","year":"2020","journal-title":"Gene"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ai, Y., Wu, S., Zou, C., and Wei, H. (J. Cell Mol. Med., 2021). Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma, J. Cell Mol. Med., Ahead of Print.","DOI":"10.1111\/jcmm.16533"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/jcb.29481","article-title":"Circular RNA circ-Foxo3 inhibits esophageal squamous cell cancer progression via the miR-23a\/PTEN axis","volume":"121","author":"Xing","year":"2020","journal-title":"J. Cell Biochem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.2147\/CMAR.S253412","article-title":"Circular RNA FOXO3 Suppresses Bladder Cancer Progression and Metastasis by Regulating MiR-9-5p\/TGFBR2","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.2147\/OTT.S215823","article-title":"Circular RNA circ-Foxo3 induced cell apoptosis in urothelial carcinoma via interaction with miR-191-5p","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.2147\/OTT.S243571","article-title":"CircFoxo3 Promotes Adriamycin Resistance through Regulation of miR-199a-5p\/ATP Binding Cassette Subfamily C Member 1 Axis in Hepatocellular Carcinoma","volume":"13","author":"Huang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_127","first-page":"1402","article-title":"Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses","volume":"38","author":"Du","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1111\/ajt.16475","article-title":"Circular RNA Foxo3 in cardiac ischemia-reperfusion injury in heart transplantation: A new regulator and target","volume":"21","author":"Su","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Yang, Z., Huang, C., Wen, X., Liu, W., Huang, X., Li, Y., Zang, J., Weng, Z., Lu, D., and Tsang, C.K. (Mol. Ther., 2021). Circular RNA circ-FoxO3 attenuates blood-brain barrier damage by inducing autophagy during ischemia\/reperfusion, Mol. Ther., Ahead of Print.","DOI":"10.1016\/j.ymthe.2021.11.004"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10571-020-00817-2","article-title":"Silencing of circFoxO3 Protects HT22 Cells from Glutamate-Induced Oxidative Injury via Regulating the Mitochondrial Apoptosis Pathway","volume":"40","author":"Lin","year":"2020","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2021.01.037","article-title":"Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy","volume":"79","author":"Li","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/modpathol.2017.74","article-title":"Androgen-receptor splice variant-7-positive prostate cancer: A novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients","volume":"31","author":"Li","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41419-018-1048-1","article-title":"Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"10739","DOI":"10.1038\/s41598-019-47189-2","article-title":"Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide","volume":"9","author":"Greene","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.2147\/OTT.S309917","article-title":"Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer","volume":"14","author":"Yu","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/med-2019-0097","article-title":"CircRNA-UCK2 Increased TET1 Inhibits Proliferation and Invasion of Prostate Cancer Cells via Sponge MiRNA-767-5p","volume":"14","author":"Xiang","year":"2019","journal-title":"Open Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.omtn.2020.09.032","article-title":"Overexpression of circRNA circUCK2 Attenuates Cell Apoptosis in Cerebral Ischemia-Reperfusion Injury via miR-125b-5p\/GDF11 Signaling","volume":"22","author":"Chen","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.omtn.2021.02.011","article-title":"Comprehensive characterization of a drug-resistance-related ceRNA network across 15 anti-cancer drug categories","volume":"24","author":"Liu","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1158\/1078-0432.CCR-14-1174","article-title":"Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy","volume":"21","author":"Qiu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1138050","article-title":"Redirection of silencing targets by adenosine-to-inosine editing of miRNAs","volume":"315","author":"Kawahara","year":"2007","journal-title":"Science"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"41442","DOI":"10.1074\/jbc.M111.301481","article-title":"The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells","volume":"286","author":"Epis","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-11-0337","article-title":"The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2","volume":"10","author":"Young","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1101\/gad.1812509","article-title":"HuR recruits let-7\/RISC to repress c-Myc expression","volume":"23","author":"Kim","year":"2009","journal-title":"Genes Dev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/0008-5472.CAN-13-1568","article-title":"Circular RNA and miR-7 in cancer","volume":"73","author":"Hansen","year":"2013","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.12.036","article-title":"Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1\/miR-195-5p\/29a-3p\/29c-3p\/CDC42 signals","volume":"394","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2019000802","article-title":"circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression","volume":"134","author":"Sun","year":"2019","journal-title":"Blood"},{"key":"ref_151","first-page":"1752","article-title":"Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4\/Eg5 axis","volume":"53","author":"Liu","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrendo.2014.35","article-title":"Autophagy\u2014A key player in cellular and body metabolism","volume":"10","author":"Kim","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-007-9873-4","article-title":"Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization","volume":"112","author":"Qadir","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/onc.2014.25","article-title":"Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model","volume":"33","author":"Nguyen","year":"2014","journal-title":"Oncogene"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/cbin.11401","article-title":"Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small-cell lung cancer cells by regulating autophagy","volume":"44","author":"Kong","year":"2020","journal-title":"Cell Biol. Int."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"109064","DOI":"10.1016\/j.biopha.2019.109064","article-title":"circMTO1 promotes tumorigenesis and chemoresistance of cervical cancer via regulating miR-6893","volume":"117","author":"Chen","year":"2019","journal-title":"Biomed. Pharm."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.18632\/aging.101674","article-title":"Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation","volume":"10","author":"Liu","year":"2018","journal-title":"Aging"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"106198","DOI":"10.1016\/j.leukres.2019.106198","article-title":"CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy","volume":"85","author":"Shang","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"117255","DOI":"10.1016\/j.lfs.2020.117255","article-title":"Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia","volume":"243","author":"Cao","year":"2020","journal-title":"Life Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","article-title":"Cancer Stem Cells: Basic Concepts and Therapeutic Implications","volume":"11","author":"Nassar","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-020-1134-8","article-title":"Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340","volume":"19","author":"Jian","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1002\/jcb.29575","article-title":"miR-449c-5p availability is antagonized by circ-NOTCH1 for MYC-induced NOTCH1 upregulation as well as tumor metastasis and stemness in gastric cancer","volume":"121","author":"Zhao","year":"2020","journal-title":"J. Cell Biochem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/cddis.2011.61","article-title":"Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters","volume":"2","author":"Saxena","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.omtn.2019.05.005","article-title":"Targeting the circBMPR2\/miR-553\/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer","volume":"17","author":"Liang","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1038\/s41388-019-0926-z","article-title":"circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p\/PBLD axis in breast cancer","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/s41418-019-0455-x","article-title":"Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-\u03b2 signalling","volume":"27","author":"Huang","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-018-0557-9","article-title":"The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells","volume":"11","author":"Joseph","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-020-01149-x","article-title":"Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1","volume":"19","author":"Hong","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"12412","DOI":"10.18632\/aging.102580","article-title":"CircRNA_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217\/Wnt3 pathway","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijbiomac.2018.11.273","article-title":"CircVRK1 regulates tumor progression and radioresistance in esophageal squamous cell carcinoma by regulating miR-624-3p\/PTEN\/PI3K\/AKT signaling pathway","volume":"125","author":"He","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"581558","DOI":"10.3389\/fcell.2020.581558","article-title":"Exosomal circRN.NAs: Sorting Mechanisms, Roles and Clinical Applications in Tumors","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-18-1447","article-title":"FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1038\/s41598-019-53063-y","article-title":"Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer","volume":"9","author":"Hon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/1878-0261.12629","article-title":"Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer","volume":"14","author":"Wang","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4149\/neo_2020_200417N414","article-title":"Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p","volume":"68","author":"Xu","year":"2021","journal-title":"Neoplasma"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.18632\/aging.203011","article-title":"Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p\/ROR1 axis in non-small cell lung cancer","volume":"13","author":"Yang","year":"2021","journal-title":"Aging"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.03.002","article-title":"Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma","volume":"479","author":"Ding","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","article-title":"CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1","volume":"5","author":"Xu","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4274\/tjh.galenos.2020.2020.0243","article-title":"Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma","volume":"37","author":"Luo","year":"2020","journal-title":"Turk. J. Haematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.3802\/jgo.2020.31.e75","article-title":"Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells","volume":"31","author":"Luo","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/cbin.11532","article-title":"Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner","volume":"45","author":"Pan","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1038\/s41388-021-01960-w","article-title":"Hypoxic exosomal HIF-1\u03b1-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis","volume":"40","author":"Zeng","year":"2021","journal-title":"Oncogene"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","article-title":"Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC","volume":"20","author":"Chen","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-020-01222-5","article-title":"Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3747\/co.27.5121","article-title":"Immune Checkpoint Inhibitors in Genitourinary Malignancies","volume":"27","author":"Thana","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/aging.203576","article-title":"Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p\/EGFR axis","volume":"13","author":"Ge","year":"2021","journal-title":"Aging"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-020-01213-6","article-title":"Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis","volume":"19","author":"Huang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"FSO674","DOI":"10.2144\/fsoa-2020-0210","article-title":"Urologic malignancies: Advances in the analysis and interpretation of clinical findings","volume":"7","author":"Crocetto","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtn.2018.09.010","article-title":"Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation","volume":"13","author":"Liu","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-020-01184-8","article-title":"CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17","volume":"19","author":"Han","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-17-2808","article-title":"The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma","volume":"78","author":"Qiu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-018-0935-5","article-title":"Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1\/mTOR pathway","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:12Z","timestamp":1760134632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":198,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040866"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040866","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]}}}